Federal Circuit Affirms Patent Invalidity, Ending Enanta's Paxlovid Damages Claim
ENTA has more than doubled off its 52-week low of $6.435 on elevated volume (2.3× avg).
Summary
The Federal Circuit affirmed the invalidity of Enanta Pharmaceuticals' patent related to Pfizer's Paxlovid, confirming a prior adverse ruling. This decision effectively ends Enanta's ability to claim damages from Pfizer for the successful COVID-19 antiviral drug. This is a significant legal setback, removing a potential revenue stream that could have been material for the company. This news follows an 8-K filed minutes earlier and previous disclosures regarding the ongoing patent dispute.
At the time of this announcement, ENTA was trading at $14.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $408.8M. The 52-week trading range was $6.44 to $17.15. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.